What is Total Kidney Volume (TKV) and Why is it Important to Me?

Living with PKD | Newly Diagnosed
Back to Search
Wednesday, May 25, 2022 | 7 p.m. CDT
Dr. Ronald Perrone explains total kidney volume (TKV), what it indicates, measurement methods, and selecting the right provider.

This patient education session is supported by a sponsorship to the PKD Foundation from Otsuka Pharmaceuticals, Inc.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a chronic, genetic disorder marked by growth of fluid-filled cysts in the kidneys. Complications include hypertension, side pain, blood in urine decreased kidney function, and sometimes kidney failure. Total Kidney Volume (TKV) is the primary measure of kidney growth and can provide information on disease status and its progression. MRI or CT scan are the best methods to obtain TKV measurements. Selecting a provider that is educated on ADPKD and who understands your disease management goals is critical.

Learning objectives

—Disseminate information about TKV with respect to how it is measured, what it measures, and its implications for disease progression
—Education on what treatments have been shown to affect TKV measurements and how to discuss options with the healthcare team
—Empower patients with ADPKD and their caregivers to better engage with their healthcare team


Ronald D. Perrone, M.D.

I am a member of the Division of Nephrology at Tufts Medical Center and Professor of Medicine at Tufts University School of Medicine. I established the Center for Polycystic Kidney Disease at Tufts Medical Center and work closely with clinical colleagues in the care of patients with PKD. I have had a long-standing and wide-ranging interest in ADPKD, focusing primarily on clinical trials and use of total kidney volume as a potential regulatory endpoint. I served as the clinical lead and co-director of the PKD Outcomes Consortium whose work led to qualification of total kidney volume as a prognostic biomarker by FDA and EMA. I have participated in a number of clinical trials in ADPKD serving as the Boston site Principal Investigator and member of the Steering Committees for the HALT PKD study, the TEMPO 3/4 and REPRISE trials of tolvaptan in ADPKD, the TAME-PKD study of metformin, the Venglustat study, and the Action study of lixivaptan. I also serve as Boston site PI for the Tesevatinib and Bardoxolone (Falcon) studies.

Related Resources



What to Expect from the ARPKD EL-PFDD Meeting On August 29, 2023 the PKD Foundation will hold its first ever Externally Led Patient-focused Drug Development (EL-PFDD) Meeting on Autosomal Recessive PKD (ARPKD) and Congenital Hepatic Fibrosis (CHF). Should you attend the meeting? What should you...

ADPKD Registry Annual Report 2022

ADPKD Registry Annual Report 2022

The PKDF Research team is excited to expand the features available in the ADPKD Registry in summer 2023. This project has been carefully planned and executed with our patients at the center. The last few years have been spent building the largest ADPKD patient-reported outcomes dataset.